Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DV-10 |
| Synonyms | |
| Therapy Description |
DV-10 is a tumor-specific, replication competent adenovirus engineered to express IL18 and CXCL9, as well as secreted and membrane-bound forms of TNFRSF17 (BCMA), which potentially increases immune activation and infiltration into the tumor microenvironment (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_2, 393). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DV-10 | DV10|DV 10 | DV-10 is a tumor-specific, replication competent adenovirus engineered to express IL18 and CXCL9, as well as secreted and membrane-bound forms of TNFRSF17 (BCMA), which potentially increases immune activation and infiltration into the tumor microenvironment (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_2, 393). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|